Clinical Trials Directory

Trials / Completed

CompletedNCT06497517

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

A Phase 1, Single Center, Single Dose, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Food Effect on the Pharmacokinetics of Camlipixant in Healthy Male and Female Participants

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Bellus Health Inc. - a GSK company · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.

Conditions

Interventions

TypeNameDescription
DRUGGSK5464714- CamlipixantGSK5464714- Camlipixant will be administered

Timeline

Start date
2024-07-09
Primary completion
2024-08-22
Completion
2024-08-26
First posted
2024-07-11
Last updated
2025-02-07

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06497517. Inclusion in this directory is not an endorsement.